

## INSERT THE FACTS INTO THE IMPLANON NXT® CONVERSATION

Image not to scale. Actual implant length is 4cm.


IMPLANON NXT® is indicated for contraception. Safety and efficacy profiles have been studied in women between 18 and 40 years of age.



### All progestagen-only contraceptives may cause irregular bleeding<sup>1</sup>

Menstrual bleeding pattern changes may occur with ALL progestagen-only contraceptives. This may include frequent, heavy, prolonged, spotting, and other patterns of bleeding irregularity.<sup>1</sup> This bleeding profile may be expected with IMPLANON NXT®.<sup>1</sup>

#### IN FACT



#### Women who had unfavorable bleeding patterns in the first 90 days had at least a 50% chance of improving<sup>1</sup>

If you have bleeding issues with IMPLANON NXT®, with time the bleeding pattern may improve.<sup>1</sup>



#### About 1 in 5 women reported frequent and/or prolonged bleeding with IMPLANON NXT®.<sup>2</sup>

Keeping a daily journal of your bleeding pattern may help you get used to how IMPLANON NXT® may affect your bleeding pattern.



#### About 1 in 5 women experienced amenorrhea with IMPLANON NXT®.<sup>2</sup>

The absence of bleeding does not mean you are pregnant. IMPLANON NXT® is >99% effective in preventing pregnancy.

IMPORTANT: Rule out pregnancy before inserting the implant.



#### In clinical trials,<sup>1</sup> 10.4% of women discontinued IMPLANON NXT® because of bleeding changes<sup>3</sup>

The majority of women in clinical trials opted to continue using IMPLANON NXT® despite the bleeding changes they may have experienced.<sup>3</sup>

\*A study reviewed data from 11 clinical trials to evaluate bleeding patterns associated with Implanon® (etonogestrel). Bleeding, spotting, dysmenorrhea, and reasons for discontinuation were assessed.

†In clinical trials of the non-radiopaque etonogestrel implant.

‡A integrated safety analysis included 11 international clinical trials to evaluate the tolerability and clinical safety of non-radiopaque etonogestrel implant in 942 women with normal menstrual cycles.

#### References:

1. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon® on menstrual bleeding patterns, *Eur J Contracept Reprod Health Care*. 2008;13(suppl 1):13-28. doi:10.1080/13625180801959931.
2. Implanon NXT® Prescribing Information. Organon Malaysia, September 2021.
3. Blumenthal PD, et. al. Tolerability and clinical safety of Implanon®, *Eur J Contracept Reprod Health Care*. 2008-13(S1): 29-36.



### Selected Safety Information for Implanon NXT® (etonogestrel)

**COMPOSITION:** Each radiopaque implant contains 68 mg of etonogestrel. **THERAPEUTIC INDICATIONS:** Contraception. **DOSAGE AND ADMINISTRATION:** Pregnancy should be excluded before insertion of Implanon NXT®. Healthcare professionals (HCPs) are strongly recommended to participate in a training session to become familiar with the use of the Implanon NXT® applicator and the techniques for insertion and removal of the Implanon NXT® implant and where appropriate, request supervision prior to inserting or removing the implant. Subdermal insertion. No preceding hormonal contraceptive use in the past mth: Insert on day 1 & 5 of the menstrual cycle. Changing from combined oral contraceptive (COC), vaginal ring or transdermal patch: Insert preferably on the day after last active COC tab, but at the latest on the day following the usual tab-free interval or last placebo COC tab. Changing from progestagen-only method [pill, injectable, implant or intrauterine system (IUS)] Injectable contraceptives: Insert when the next injection would be due. Pill: Insert within 24 hr any day after last pill. Implant or IUS: Insert on the same day of removal. Post 1<sup>st</sup>-trimester abortion Insert within 5 days following 1st trimester abortion or miscarriage. Post 2<sup>nd</sup>-trimester abortion Insert between day 21-28 following 2<sup>nd</sup> trimester abortion or miscarriage. Postpartum with breastfeeding: Insert after 4<sup>th</sup> postpartum week. Postpartum without breastfeeding: Insert between 21-28 days postpartum. **CONTRAINDICATIONS:** Progestagen-only contraceptives should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during the use of Implanon NXT®, the product should be stopped immediately. · Known or suspected pregnancy. · Active venous thromboembolic disorder. · Known or suspected sex steroid sensitive malignancies · Presence or history of liver tumours (benign or malignant). · Presence or history of severe hepatic disease as long as liver function values have not returned to normal. · Undiagnosed vaginal bleeding. · Hypersensitivity to the active substance or to any of the excipients of Implanon NXT® **SPECIAL WARNINGS & PRECAUTIONS:** If any of the conditions/risk factors mentioned below is present, the benefits of progestagen use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start with Implanon NXT®. · Carcinoma of the Breast · Liver Disease · Thrombotic and Other Vascular Events · Elevated Blood Pressure · Carbohydrate and Lipid Metabolic Effects · Chloasma · Body Weight · Complications of Insertion · Ovarian Cysts · Ectopic Pregnancies · Other Conditions The following conditions have been reported both during pregnancy and during sex steroid use, but an association with the use of progestagens has not been established: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; hemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss and (hereditary) angioedema. **ADVERSE REACTIONS:** During the use of Implanon NXT, women are likely to have changes in their menstrual bleeding pattern. These may include changes in bleeding frequency (absent, less, more frequent or continuous), intensity (reduced or increased) or duration. Possibly related undesirable effects reported in clinical trials: Vaginal infection; headache; acne; breast pain & tenderness, irregular menstruation; increased weight. Increased appetite; affect lability, depression, nervousness, decreased libido; dizziness; hot flush; abdominal pain, nausea, flatulence; alopecia; dysmenorrhea, ovarian cyst; implant site pain & reaction, fatigue, flu-like illness, pain; decreased weight.

**Before initiating therapy, please consult the full Prescribing Information.**

This material is only for Healthcare Professionals.



#### Organon Malaysia Sdn. Bhd.

Mercu 2, Level 40, Office 39-W022, No 3 Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Wilayah Persekutuan, Malaysia.

Tel No.: +603-2386 2000 | Fax No.: +603-2386 2100

© 2022 Organon group of companies. All rights reserved.

MY-XPL-110014 May/2022